The complex management of the breast angiosarcoma: a retrospective study

Background/Aim: Breast angiosarcoma is a rare and aggressive disease with a poor prognosis. Two subtypes have been identified: primary angiosarcoma (PBA) and secondary breast angiosarcoma (SBA). In this retrospective analysis, we describe and compare our institute experience with the data existing in the literature. 
Materials and Methods: We included in our analysis 29 patients who received a diagnosis of PBA or SBA between 2006 and 2019. 
Results: All patients received surgery as frontline treatment, but only 6 patients underwent to adjuvant treatment. Neoadjuvant chemotherapy was administeredon 2 patients. The preferred chemotherapeutic regimen was taxanes with or without gemcitabine, andassociated with anthracyclines. A lower median RFS and OS was reported in patients with PBA compared to those with SBA, but the difference observed was not statistically significant. Patients with PBA had alower median age at the diagnosis (38 vs 75).
Conclusion: In our analysis we have shown a lower median RFS and OS in patients with PBA compared with those with SBA, and a significantly younger age at diagnosis in patients affected by PBA.
